BACKGROUND: Pentavalent antimony (Sb(v)) is the mainstay therapy for mucosal leishmaniasis (ML), but it is toxic, and relapses are common. Immunotherapy using a mixture of killed parasites, with or without bacille Calmette-Guerin, is an alternative but is used sporadically because of inconsistent results. METHODS: We developed a defined immunotherapeutic antigen preparation for use in an observational, open-label trial to treat 6 patients with ML with a history of Sb(v) therapy failure. All patients were treated with the antigens thiol-specific antioxidant, Leishmania major stress inducible protein 1, Leishmania elongation initiation factor, and Leishmania heat shock protein 83, plus granulocyte-macrophage colony-stimulating factor. Patients underwent clinical and pathological evaluations before the initiation of immunotherapy and at 3, 6, 9, 12, 18, 24, and 60 months after. RESULTS: One month after the third injection, 1 patient showed complete clinical remission (CC) and remained disease free for the duration of the study. At the 9-month follow-up examination, 5 patients showed CC, and all patients were asymptomatic at a subsequent 5-year follow-up examination. CONCLUSIONS: These data support the concept that vaccine therapy with a defined antigen combination, used with standard chemotherapy, is a safe and effective approach to treat drug-refractory ML.
BACKGROUND: Pentavalent antimony (Sb(v)) is the mainstay therapy for mucosal leishmaniasis (ML), but it is toxic, and relapses are common. Immunotherapy using a mixture of killed parasites, with or without bacille Calmette-Guerin, is an alternative but is used sporadically because of inconsistent results. METHODS: We developed a defined immunotherapeutic antigen preparation for use in an observational, open-label trial to treat 6 patients with ML with a history of Sb(v) therapy failure. All patients were treated with the antigens thiol-specific antioxidant, Leishmania major stress inducible protein 1, Leishmania elongation initiation factor, and Leishmania heat shock protein 83, plus granulocyte-macrophage colony-stimulating factor. Patients underwent clinical and pathological evaluations before the initiation of immunotherapy and at 3, 6, 9, 12, 18, 24, and 60 months after. RESULTS: One month after the third injection, 1 patient showed complete clinical remission (CC) and remained disease free for the duration of the study. At the 9-month follow-up examination, 5 patients showed CC, and all patients were asymptomatic at a subsequent 5-year follow-up examination. CONCLUSIONS: These data support the concept that vaccine therapy with a defined antigen combination, used with standard chemotherapy, is a safe and effective approach to treat drug-refractory ML.
Authors: Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed Journal: Clin Vaccine Immunol Date: 2011-06-01
Authors: Felipe F Tuon; Valdir S Amato; Hélio A Bacha; Tariq Almusawi; Maria I Duarte; Vicente Amato Neto Journal: Infect Immun Date: 2007-12-10 Impact factor: 3.441
Authors: Jeffrey M Bethony; Rhea N Cole; Xiaoti Guo; Shaden Kamhawi; Marshall W Lightowlers; Alex Loukas; William Petri; Steven Reed; Jesus G Valenzuela; Peter J Hotez Journal: Immunol Rev Date: 2011-01 Impact factor: 12.988
Authors: Allison K Ehrlich; Olga L Fernández; Daniel Rodriguez-Pinto; Tiago M Castilho; Maria J Corral Caridad; Karen Goldsmith-Pestana; Nancy Gore Saravia; Diane McMahon-Pratt Journal: Infect Immun Date: 2017-02-23 Impact factor: 3.441
Authors: Sanjay R Mehta; Robert Huang; Meng Yang; Xing-Quan Zhang; Bala Kolli; Kwang-Poo Chang; Robert M Hoffman; Yasuyuki Goto; Roberto Badaro; Robert T Schooley Journal: Clin Vaccine Immunol Date: 2008-10-22